UBS Maintains Neutral on Hologic, Lowers Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Elizabeth Garcia has maintained a Neutral rating on Hologic (NASDAQ:HOLX) but has reduced the price target from $91 to $78.
November 16, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Elizabeth Garcia maintains a Neutral rating on Hologic but lowers the price target from $91 to $78.
The reduction in price target by UBS suggests a less optimistic outlook on Hologic's stock value, which could lead to a negative short-term impact on the stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100